Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nueva inmunoterapia contra el cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20160809001
Publicado:
30/08/2016
Caducidad:
29/08/2017
Resumen:
Una pyme alemana de biotecnología está desarrollando un nuevo agente inmunoterapéutico basado en lectina vegetal. La proteína ha sido probada en diferentes tipos de cáncer en estudios de fase I y II. En la fase II del melanoma se ha demostrado una eficacia muy similar en una población estratificada a la eficacia de los últimos productos inmunoterapéuticos en desarrollo. Tras la prueba de concepto en ensayos clínicos, la empresa busca socios industriales interesados en continuar con las pruebas y comercializar la tecnología bajo acuerdos de investigación, licencia o comercialización con asistencia técnica.

Details

Tittle:
New immunotherapy against cancer
Summary:
A German biotech SME is developing a novel immunotherapeutic agent based on plant lectin. The protein has been tested in different cancers in phase I and II studies. The latest phase II in melanoma showed in a stratified population very similar efficacy as the latest immunotherapeutics in development. Following the proof of concept in clinical trials, the SME seeks industrial partners for fiurther testing and marketing within research, licensing or commercial agreements with technical assistance
Description:
Melanoma is the most serious and aggressive type of skin cancer and one of the cancers with growing incidences in many European, especially in Eastern European countries. In Russia and other Eastern countries chemotherapy is still widely used despite a very low improvement of average survival time. Recently developed treatments from Western countries like ipilimumb/yervoy, nivolumb, pembrolizumab, vemurafenib or combination of these pharmaceuticals are not or rarely used due to the very high costs of the treatments or due to the lack of approvals.

A research team of a small German biotech company developed a plant protein,manufactured by recombinant DNA techniques in E. coli. It acts as an immunotherapeutic inducing a close collaboration between cells of the innate and adaptive immune systems to fight cancer cells. Its mechanism of action supports subcutaneous or local application.

The medical effectiveness of the pharmaceutical has been proved in phase I and II trials. The antitumor effect was proven in trials with different types of cancers. Therefore the second and third level phase clinical tests should further prove effect with the objective to get approvals.

Due to the comparably low production costs the new drug could be able to replace the chemotherapy at affordable costs.

In the next step phase II and III trials have to be undertaken by an experienced oncologic clinic for the accreditation of the drug and the proof of efficacy. For these trials a research cooperation should be initiated.

For the accreditation procedures and the following market introduction a close cooperation with a pharmaceutical company is sought. The company sought should have some experience in the accreditation and the introduction of drugs in the market. This cooperation could be implemented within the framework of a licensing agreement or a commecial agreement with technical assistance. The German biotech company will give technical assistance with the trials and will provide drug examples for the tests.

Advantages and Innovations:
· Innovative immunotherapeutic drug
· Higher efficacy in metastatic melanoma with median overall survival of more than 14 months shown in a phase II study
· Stratified population with easy accessible biomarker
· Potential in a large number of cancers
· High potential for combination therapy
· Very low dose requirements / lower adverse effects compared to comparable drugs
· Excellent safety profil
· Even more effective in some difficult to treat subgroups
· Comparably low production requirements and production costs
· Patent protection by granted patent as well as recently filed patent applications
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how,Patent(s) applied for but not yet granted,Patents granted
CommeR Statunts Regarding IPR Status:
The company has 3 patent applications (one of them for melanoma) and one patent covering medical uses of Aviscumine.
· The company has one patent granted covering a pharmaceutical formulation of Aviscumine (formulation patent).
· A patent application covering the manufacturing process of Aviscumine is in preparation by the company (process patent).
· A special data protection will be granted for biopharmaceuticals in most countries: For example in Europe the first NDA of Aviscumine will have 10 years of market exclusivity.

Partner sought

Type and Role of Partner Sought:
Pharmaceutical company with market experience with research potential
· The company should organise the phase II and III studies as well as the accreditation of the pharmaceutical
· Experience in putting pharmaceutics to market
Clinics specialised in oncological testings
· Clinics experienced in clinical phase II and III tests with oncological departments

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001002 Investigaciones clínicas, ensayos
06001015 Productos farmacéuticos / medicamentos